Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 9/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20641622 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2NAMPTEPHX2RECQL | |
| SCHEMBL8217782 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2NAMPTEPHX2RECQL | |
| SCHEMBL16356995 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2NAMPTEPHX2RECQL | |
| SCHEMBL26873336 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2NAMPTEPHX2RECQL | |
| SCHEMBL24433430 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2NAMPTEPHX2RECQL | |
| SCHEMBL16356994 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2NAMPTEPHX2RECQL | |
| SCHEMBL8214686 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2NAMPTEPHX2RECQL | |
| SCHEMBL24145962 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2NAMPTEPHX2RECQL | |
| SCHEMBL1709273 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2NAMPTEPHX2GPR119 | |
| Hydrochloric Acid SCHEMBL30777278 | 0.82 | USP2 (0.46) | USP2SMN1; SMN2NAMPTEPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119076-B | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东有限责任公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-3788043-B1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| EP-4244208-A1 | A MAGL INHIBITOR | H. Lundbeck A/S (DK) | 2023-09-20 | — | — | EP | disclosed |
| CN-116547274-A | MAGL inhibitors | H.隆德贝克有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022101412-A1 | A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | WO | disclosed |
| US-20220153721-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | US | disclosed |
| WO-2022101412-A1 | A MAGL INHIBITOR | H. LUNDBECK A/S (DK) | 2022-05-19 | — | — | WO | disclosed |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210070745-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2021-03-11 | — | — | US | disclosed |
| CN-112119076-A | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东公司 | 2020-12-22 | — | — | CN | disclosed |
| US-9326985-B2 | Heteroaryl pyridone and aza-pyridone amide compounds | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150011461-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS | GENENTECH, INC. (US) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | USP2 4415/4885SMN1; SMN2 2483/4885NAMPT 841/4885 |
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | USP2 1558/4885SMN1; SMN2 803/4885NAMPT 2121/4885 |
| US-20210070745-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | USP2 4415/4885SMN1; SMN2 2483/4885NAMPT 841/4885 |
| US-20150011461-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE AMIDE COMPOUNDS | BTK, TYK2, LCK | USP2 3612/4885SMN1; SMN2 4078/4885NAMPT 866/4885 |
| US-20220153721-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | USP2 1558/4885SMN1; SMN2 803/4885NAMPT 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.